Palisade Bio PALI
Palisade Bio reports $14.62 million net loss for Q3 2026
Palisade Bio (PALI) filed a 10-Q with the SEC on Nov 10, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001357459-26-000024
- Revenue: $0 for the three months ended Sep 30, 2026
- Net loss: $14.62 million for the three months ended Sep 30, 2026
- Cash and equivalents: $113.61 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
